Subscribe What is EndoPredict? EndoPredict is a 2nd generation multi-gene breast cancer recurrence test for pre- or postmenopausal women newly diagnosed with early-stage breast cancer.
Created for the purpose of highly accurate assessment of 5 to year risk of distant breast cancer genetic markers of the disease EndoPredict combines into an unique indicator EPClin score gene expression with clinically pathological features providing outstanding prognostic breast cancer genetic markers that will ensure the healthcare professional that chemotherapy is or is not required to accompany endocrine treatment.
Considering these breast cancer genetic markers, realizing that the cancer has a high or low risk of recurrence can help patients and doctors decide if chemotherapy after surgery is or is not necessary to accompany endocrine therapy.
What DNA sample is required to perform the test? EndoPredict requires a simple tumor tissue sample that is customarily prepared for the pathology exam upon surgical tumor removal.
Subiecte în Health
The latest diagnostic and prognostic technology allows healthcare specialists to determine suitable treatment procedures based completely on the needs and DNA of the patient.
Therefore, the decision of breast cancer therapy increasingly depends on your own mix of gene markers.
- Papillomavirus quelle maladie
- The aim of current work is to update the information about the clinical practice implementation of molecular markers used for diagnosis, prognosis and individual therapy in women breast cancer.
- Departamentul lui nu va găsi un tratament pentru cancerul de sân.
Северная Дакота, - вслух произнесла она, пытаясь своим умом криптографа проникнуть в скрытый смысл этого имени.
In this context, EndoPredict reveals critical information about the way that a tumor is likely to react at a genetic level. Why is EndoPredict relevant? At the same time it can convince those at low risk of recurrence that chemotherapy is not mandatory. Thus, the test is practically an important step ahead towards the goal of truly customized care, helping breast cancer therapists to avoid both over- and under treatment of breast cancer with chemotherapy. When do breast cancer metastases occur?
Markeri moleculari utilizaţi pentru diagnostic, prognostic şi terapie în cancerul mamar - review
Breast cancer metastases mostly happen within the first three years following the initial diagnosis. One of the objectives of EndoPredict test is to calculate the tendency for cancer recurrence or late metastases. What is the best treatment to lower the risk of developing a recurrence of the breast cancer?
For early and locally advanced breast cancer genetic markers cancer the first clinical step is, of course, to surgically remove the tumor.
The next step requires a more complex decision.
- Mutaţii BRCA1 şi BRCA2 – cancer ereditar sân/ovar | Synevo
- Does hpv cause respiratory papillomatosis lesions
- EndoPredict – Nucleoshealthcare
- Numeroasele studii efectuate au aratat ca mutatiile genelor BRCA1 si BRCA2 care afecteaza linia germinala sunt responsabile de marea majoritate a cancerelor ereditare de san si ovar1;7.
- Pentru bărbaţii cu mutaţii BRCA2 riscul cumulat de cancer mamar până la vârsta de 80 ani a fost estimat la 6.
Around half of the intermediate patients currently receive unnecessary chemotherapy, which is very stressful for the organism, has serious side-effects, is toxic by nature and has a significant impact on mortality.
Breast cancer genetic markers that reason, it is very important to be able to identify the patients who would not adequately benefit from chemotherapy in any case and to be able to provide a more focused care, including systemic endocrine therapy, instead.
EndoPredict manages to make this happen.
Mutatii BRCA1 cancer ereditar san/ovar
The result? The ones who would not adequately benefit from chemotherapy can be spared from this treatment and its correlated side-effects.
Genetics and Breast Cancer - Mayo Clinic
How does the test work? Performed on preserved breast tumor tissue that was removed during the initial biopsy or surgery, the EndoPredict test analyzes the activity of rigorously selected prolipherative and hormone-receptor-related genes in breast cancer cells.
Mutaţii BRCA1 şi BRCA2 – cancer ereditar sân/ovar
These genes are linked to the possibility that the cancer will come back in a different part of the body within 15 years after initial diagnosis. The test includes the size of the breast tumor and whether or not the cancer is in the lymph nodes when calculating the risk score.
The scores are recognized either low-risk or high-risk: an EPclin Risk Score higher than 3.
With the help of our partner physicians, experts in genetic counseling in breast cancer, you will find out the benefits of the EndoPredict test, understand the clinical results and make the right decisions for your future health. Fill this form to get in touch with a doctor for a clinic consultation and testing.